MARAbio Revenue and Competitors
Estimated Revenue & Valuation
- MARAbio's estimated annual revenue is currently $2.8M per year.
- MARAbio's estimated revenue per employee is $155,000
- MARAbio's total funding is $25M.
Employee Data
- MARAbio has 18 Employees.
- MARAbio grew their employee count by 64% last year.
MARAbio's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Advisor/Head Clinical Development | Reveal Email/Phone |
2 | Head Marketing | Reveal Email/Phone |
3 | Head Assay Development | Reveal Email/Phone |
4 | Clinical Operations Consultant | Reveal Email/Phone |
MARAbio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 64% | $25.1M | N/A |
#3 | $1.4M | 9 | 0% | N/A | N/A |
#4 | $7.1M | 46 | 39% | N/A | N/A |
#5 | $1.4M | 9 | -50% | N/A | N/A |
#6 | $1.4M | 9 | -10% | N/A | N/A |
#7 | $25.9M | 167 | 11% | N/A | N/A |
#8 | $1.6M | 40 | -48% | $17.8M | N/A |
#9 | $3.4M | 22 | 83% | N/A | N/A |
#10 | $2M | 13 | 0% | N/A | N/A |
What Is MARAbio?
We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.
keywords:N/A$25M
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 18 | 0% | N/A |
#2 | $0.7M | 18 | -14% | N/A |
#3 | $2.7M | 18 | N/A | N/A |
#4 | $3.6M | 18 | -5% | N/A |
#5 | $3.5M | 18 | 0% | N/A |